注射去纤苷需要注意什么？

It is suitable for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). What should I pay attention to when injecting defibrotide?

Precautions for defibrination:

1. Defibrotide needs to be administered by injection, and defibrotide must be diluted before infusion.

2. Before administration of defibrotide, confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.

3. Do not co-administer defibrotide and other intravenous drugs in the same intravenous line at the same time.

4. Bleeding:

Defibrinoside increases plasmin activity in vitro and may increase the risk of bleeding in VOD patients after hematopoietic stem cell transplantation (HSCT). Do not initiate defibrotide therapy in patients with active bleeding. Monitor patients for signs of bleeding. If a patient develops symptoms of bleeding, discontinue use and provide treatment until bleeding stops. Concomitant use of defibrotide and systemic anticoagulation or fibrinolytic therapy (not included for routine maintenance or reopening of central venous lines) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide therapy and consider delaying the use of defibrotide until the effect of the anticoagulant has diminished.   

5. Hypersensitivity reaction:

Less than 2% of treated patients experienced allergic reactions. These reactions include rash, urticaria, and angioedema. One case of an allergic reaction in a patient has been reported. Monitor patients for hypersensitivity reactions, especially those with past exposure. If a severe hypersensitivity reaction occurs, discontinue defibrotide, treat according to standard of care, and monitor until symptoms resolve.

Recommended related hot articles: /newsDetail/81071.html